LU83729A1 - Sels d'acide valproique,leur preparation et leur utilisation - Google Patents

Sels d'acide valproique,leur preparation et leur utilisation Download PDF

Info

Publication number: LU83729A1
Authority: LU; Luxembourg
Prior art keywords: acid; salt; amino acid; valproic acid; basic amino
Prior art date: 1981-11-04

Application number

LU83729A

Other languages

English (en)

French (fr)

Inventor

Arthur Marie Deboeck

Original Assignee

Galephar

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1981-11-04

Filing date

1981-11-04

Publication date

1983-09-01

1981-11-04 Application filed by Galephar filed Critical Galephar

1981-11-04 Priority to LU83729A priority Critical patent/LU83729A1/fr

1982-11-03 Priority to DE8282870062T priority patent/DE3262899D1/de

1982-11-03 Priority to AT82870062T priority patent/ATE12485T1/de

1982-11-03 Priority to EP82870062A priority patent/EP0078785B1/de

1983-09-01 Publication of LU83729A1 publication Critical patent/LU83729A1/fr

1986-05-16 Priority to US06/864,560 priority patent/US4699927A/en

Links

MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical class [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 title claims abstract 15
238000002360 preparation method Methods 0.000 title claims description 6
NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims abstract description 35
150000001413 amino acids Chemical class 0.000 claims abstract description 33
229960000604 valproic acid Drugs 0.000 claims abstract description 20
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims abstract description 13
239000004472 Lysine Substances 0.000 claims abstract description 12
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims abstract description 12
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 8
239000004475 Arginine Substances 0.000 claims abstract description 5
AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims abstract description 5
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims abstract description 5
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims abstract description 5
AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims abstract description 5
UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims abstract description 5
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims abstract description 5
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims abstract description 5
229960003104 ornithine Drugs 0.000 claims abstract description 5
239000004471 Glycine Substances 0.000 claims abstract description 4
239000007795 chemical reaction product Substances 0.000 claims abstract description 3
150000003839 salts Chemical class 0.000 claims description 24
239000002253 acid Substances 0.000 claims description 18
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
239000000203 mixture Substances 0.000 claims description 9
-1 amino acid salt Chemical class 0.000 claims description 8
238000004108 freeze drying Methods 0.000 claims description 8
238000000034 method Methods 0.000 claims description 8
239000002904 solvent Substances 0.000 claims description 8
238000000926 separation method Methods 0.000 claims description 7
238000001704 evaporation Methods 0.000 claims description 6
230000008020 evaporation Effects 0.000 claims description 6
238000001914 filtration Methods 0.000 claims description 6
239000011541 reaction mixture Substances 0.000 claims description 6
239000003960 organic solvent Substances 0.000 claims description 5
239000006185 dispersion Substances 0.000 claims description 4
OCHFNTLZOZPXFE-JEDNCBNOSA-N carbonic acid;(2s)-2,6-diaminohexanoic acid Chemical group OC(O)=O.NCCCC[C@H](N)C(O)=O OCHFNTLZOZPXFE-JEDNCBNOSA-N 0.000 claims description 3
239000000546 pharmaceutical excipient Substances 0.000 claims description 3
239000001961 anticonvulsive agent Substances 0.000 claims description 2
239000003814 drug Substances 0.000 claims description 2
238000001556 precipitation Methods 0.000 claims description 2
239000003495 polar organic solvent Substances 0.000 claims 2
150000007513 acids Chemical class 0.000 claims 1
229940125681 anticonvulsant agent Drugs 0.000 claims 1
238000004519 manufacturing process Methods 0.000 claims 1
239000008194 pharmaceutical composition Substances 0.000 claims 1
239000000047 product Substances 0.000 claims 1
229940124597 therapeutic agent Drugs 0.000 claims 1
235000001014 amino acid Nutrition 0.000 description 17
239000000243 solution Substances 0.000 description 17
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
235000018977 lysine Nutrition 0.000 description 10
238000003756 stirring Methods 0.000 description 7
239000007864 aqueous solution Substances 0.000 description 4
AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 4
239000007787 solid Substances 0.000 description 4
239000003826 tablet Substances 0.000 description 4
229940102566 valproate Drugs 0.000 description 4
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
235000009697 arginine Nutrition 0.000 description 3
239000002585 base Substances 0.000 description 3
235000014304 histidine Nutrition 0.000 description 3
239000000725 suspension Substances 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
229910052783 alkali metal Inorganic materials 0.000 description 2
230000001773 anti-convulsant effect Effects 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
239000008298 dragée Substances 0.000 description 2
150000002576 ketones Chemical class 0.000 description 2
239000007788 liquid Substances 0.000 description 2
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
239000000843 powder Substances 0.000 description 2
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical class OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
239000000654 additive Substances 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
150000001335 aliphatic alkanes Chemical class 0.000 description 1
239000003513 alkali Substances 0.000 description 1
229960003965 antiepileptics Drugs 0.000 description 1
239000002775 capsule Substances 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000000694 effects Effects 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
239000003349 gelling agent Substances 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
239000008187 granular material Substances 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
239000008188 pellet Substances 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
229920000151 polyglycol Polymers 0.000 description 1
239000010695 polyglycol Substances 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
239000000376 reactant Substances 0.000 description 1
239000012429 reaction media Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
238000005406 washing Methods 0.000 description 1
239000004552 water soluble powder Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/126—Acids containing more than four carbon atoms
- C07C53/128—Acids containing more than four carbon atoms the carboxylic group being bound to a carbon atom bound to at least two other carbon atoms, e.g. neo-acids

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

LU83729A 1981-11-04 1981-11-04 Sels d'acide valproique,leur preparation et leur utilisation LU83729A1 (fr)

Priority Applications (5)

Application Number	Priority Date	Filing Date	Title
LU83729A LU83729A1 (fr)	1981-11-04	1981-11-04	Sels d'acide valproique,leur preparation et leur utilisation
DE8282870062T DE3262899D1 (en)	1981-11-04	1982-11-03	Salts of valproic acid, their preparation and their use
AT82870062T ATE12485T1 (de)	1981-11-04	1982-11-03	Salze der valproinsaeure, ihre herstellung und ihre verwendung.
EP82870062A EP0078785B1 (de)	1981-11-04	1982-11-03	Salze der Valproinsäure, ihre Herstellung und ihre Verwendung
US06/864,560 US4699927A (en)	1981-11-04	1986-05-16	Anticonvulsant valproic acid salts

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
LU83729A LU83729A1 (fr)	1981-11-04	1981-11-04	Sels d'acide valproique,leur preparation et leur utilisation
LU83729		1981-11-04

Publications (1)

Publication Number	Publication Date
LU83729A1 true LU83729A1 (fr)	1983-09-01

Family

ID=19729754

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LU83729A LU83729A1 (fr)	1981-11-04	1981-11-04	Sels d'acide valproique,leur preparation et leur utilisation

Country Status (5)

Country	Link
US (1)	US4699927A (de)
EP (1)	EP0078785B1 (de)
AT (1)	ATE12485T1 (de)
DE (1)	DE3262899D1 (de)
LU (1)	LU83729A1 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5185159A (en) *	1983-07-20	1993-02-09	Sanofi	Pharmaceutical composition based on valproic acid and a process for preparing it
IL72381A (en) *	1983-07-20	1988-03-31	Sanofi Sa	Pharmaceutical composition based on valproic acid
US4913906B1 (en) *	1985-02-28	2000-06-06	Yissum Res Dev Co	Controlled release dosage form of valproic acid
FR2587900B1 (fr) *	1985-10-01	1988-10-07	Morelle Jean	Associations acides gras-acides amines basiques, douees de proprietes emollientes, emulsifiantes et antioxydantes, destinees a la cosmetique, la dermatologie et l'alimentation
IT1233836B (it) *	1988-01-13	1992-04-21	Euroresearch Srl	Sali idrosolubili dell'acido (+)2-(4 fluorofenil)-alfa-metil-5 benzoxazolo acetato.
US20020025341A1 (en) *	1998-12-18	2002-02-28	Yihong Qiu	Controlled release formulation of divalproex sodium
US6528090B2 (en)	1998-12-18	2003-03-04	Abbott Laboratories	Controlled release formulation of divalproex sodium
US6511678B2 (en)	1998-12-18	2003-01-28	Abbott Laboratories	Controlled release formulation of divalproex sodium
US20020031549A1 (en) *	1998-12-18	2002-03-14	Yihong Qiu	Controlled release formulation of divalproex sodium
US6713086B2 (en)	1998-12-18	2004-03-30	Abbott Laboratories	Controlled release formulation of divalproex sodium
US6419953B1 (en) *	1998-12-18	2002-07-16	Abbott Laboratories	Controlled release formulation of divalproex sodium
KR100843703B1 (ko) *	2000-07-21	2008-07-04	이섬 리서치 디벨러프먼트 컴파니 오브 더 히브루 유니버시티 오브 예루살렘	양극성 장애에서의 조증을 치료하기 위한 벨프로익산 및 2-벨프로에닉산 아미드 유도체의 용도
WO2002013766A2 (en) *	2000-08-17	2002-02-21	Teva Pharmaceutical Industries, Ltd.	Valproic acid derivatives for the treatment of pain
JP3825246B2 (ja) *	2000-11-24	2006-09-27	Ｎｅｃエレクトロニクス株式会社	化学的機械的研磨用スラリー
WO2002051402A1 (en) *	2000-12-22	2002-07-04	Abbott Laboratories	Controlled release formulation of divalproex sodium
US6610326B2 (en) *	2001-02-16	2003-08-26	Andrx Corporation	Divalproex sodium tablets
WO2004071424A2 (en) *	2003-02-05	2004-08-26	Teva Pharmaceutical Industries, Ltd.	Immediate release formulation of n-(2-propylpentanoyl)glycinamide
WO2004071421A2 (en) *	2003-02-05	2004-08-26	Teva Pharmaceutical Industries Ltd.	Sustained release formulation of n-(2-propylpentanoyl) glycinamide and related compounds
EP1633400A2 (de) *	2003-05-16	2006-03-15	Pfizer Products Inc.	Therapeutische kombinationen von atypischen antipsychotika mit gaba-modulatoren, anticonvulsiva oder benzodiazepinen
CN1309760C (zh) *	2003-10-16	2007-04-11	北京北医投资管理有限公司医药科技开发分公司	聚天冬酰甘氨酸、丙氨酸和赖氨酸及其制备方法和医药用途
CA2567249A1 (en) *	2004-04-19	2006-10-05	Jds Pharmaceuticals, Llc	Lithium combinations, and uses related thereto
US20050276848A1 (en) *	2004-06-15	2005-12-15	Nilobon Podhipleux	Sustained release neutralized divalproex sodium
US7713550B2 (en) *	2004-06-15	2010-05-11	Andrx Corporation	Controlled release sodium valproate formulation
US20050276849A1 (en) *	2004-06-15	2005-12-15	Nilobon Podhipleux	Sustained release dosage forms
EP2258359A3 (de)	2005-08-26	2011-04-06	Braincells, Inc.	Neurogenese durch Modulation des Muscarinrezeptors mit Sabcomelin
JP2009506069A (ja)	2005-08-26	2009-02-12	ブレインセルス，インコーポレイティド	ムスカリン性受容体調節による神経発生
PL1931335T3 (pl) *	2005-09-23	2010-07-30	Janssen Pharmaceutica Nv	Modulatory heksahydrocyklooktylopirazolokannabinoidowe
US7825151B2 (en) *	2005-09-23	2010-11-02	Janssen Pharmaceutica Nv	Hexahydro-cyclooctyl pyrazole cannabinoid modulators
US8378096B2 (en) *	2005-09-23	2013-02-19	Janssen Pharmaceutica N.V.	Hexahydro-cycloheptapyrazole cannabinoid modulators
US8378117B2 (en) *	2005-09-23	2013-02-19	Janssen Pharmaceutica N.V.	Hexahydro-cycloheptapyrazole cannabinoid modulators
HRP20120159T1 (hr) *	2005-09-23	2012-03-31	Janssen Pharmaceutica Nv	Modulatori heksahidro-cikloheptapirazol kanabinoida
US7790718B2 (en) *	2005-09-23	2010-09-07	Janssen Pharmaceutica Nv	Tetrahydro-cyclopentyl pyrazole cannabinoid modulators
US7985756B2 (en)	2005-10-21	2011-07-26	Braincells Inc.	Modulation of neurogenesis by PDE inhibition
WO2007053596A1 (en)	2005-10-31	2007-05-10	Braincells, Inc.	Gaba receptor mediated modulation of neurogenesis
US20070117858A1 (en) *	2005-11-23	2007-05-24	Mingde Xia	Substituted 5-heteroaryl-1-phenyl-pyrazole cannabinoid modulators
WO2007092456A2 (en) *	2006-02-03	2007-08-16	Rolls-Royce Corporation	Gas turbine engine fuel system with fuel metering valve
US20100216734A1 (en)	2006-03-08	2010-08-26	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
US8012957B2 (en) *	2006-03-27	2011-09-06	Janssen Pharmaceutica Nv	Tetrahydro-1H-1,2,6-triaza-azulene cannabinoid modulators
US20070254911A1 (en) *	2006-03-27	2007-11-01	Mingde Xia	Tetrahydro-Pyrazolo[3,4-c]Pyridine Cannabinoid Modulators
WO2007134077A2 (en)	2006-05-09	2007-11-22	Braincells, Inc.	5 ht receptor mediated neurogenesis
WO2007134136A2 (en)	2006-05-09	2007-11-22	Braincells, Inc.	Neurogenesis by modulating angiotensin
EP2068872A1 (de)	2006-09-08	2009-06-17	Braincells, Inc.	Kombinationen mit einem 4-acylaminopyridin-derivat
US20100184806A1 (en)	2006-09-19	2010-07-22	Braincells, Inc.	Modulation of neurogenesis by ppar agents
US7943653B2 (en) *	2007-08-13	2011-05-17	Janssen Pharmaceutica N.V.	Substituted 5-vinylphenyl-1-phenyl-pyrazole cannabinoid modulators
WO2010099217A1 (en)	2009-02-25	2010-09-02	Braincells, Inc.	Modulation of neurogenesis using d-cycloserine combinations
WO2016067297A1 (en) *	2014-10-27	2016-05-06	Cellix Bio Private Limited	Salts of valproic acid with piperazine, ethylenediamine, lysine and/or eicosapentaenoic ecid (epa) amine derivatives for the treatment of epilepsy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2662046A (en) *	1948-06-19	1953-12-08	Merck & Co Inc	Parenteral amino acid solution
US3024272A (en) *	1958-04-22	1962-03-06	Du Pont	Organic acid salts of basic amino acids and their use
FR2442M (fr) *	1962-10-17	1964-04-06	Henry Eugene	L'acide dipropylacétique et ses dérivés en tant que nouveuax médicaments dépresseurs du systeme nerveux central.

1981
- 1981-11-04 LU LU83729A patent/LU83729A1/fr unknown
1982
- 1982-11-03 DE DE8282870062T patent/DE3262899D1/de not_active Expired
- 1982-11-03 AT AT82870062T patent/ATE12485T1/de not_active IP Right Cessation
- 1982-11-03 EP EP82870062A patent/EP0078785B1/de not_active Expired
1986
- 1986-05-16 US US06/864,560 patent/US4699927A/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US4699927A (en)	1987-10-13
DE3262899D1 (en)	1985-05-09
EP0078785A1 (de)	1983-05-11
ATE12485T1 (de)	1985-04-15
EP0078785B1 (de)	1985-04-03

Publication	Publication Date	Title
EP0078785B1 (de)	1985-04-03	Salze der Valproinsäure, ihre Herstellung und ihre Verwendung
LU83423A1 (fr)	1981-09-11	Pneumatique radial pour vehicules tout-terrain
EP0748315B1 (de)	2004-01-07	Verwendung von imidazol-derivaten zur behandlung von beschwerden an denen angiotensin rezeptoren at1 und at2 beteiligt sind, diese verbindungen, deren herstellung, verwendung als medikamente, und pharmazeutische zusammensetzungen die sie enthalten
EP0318377A2 (de)	1989-05-31	Enantiomere Derivate von Aminosäure, Verfahren zu deren Herstellung und deren therapeutische Verwendung
EP0015038B1 (de)	1984-12-19	Ein Diphenylhydantoin-Derivat enthaltende pharmazeutische Zusammensetzung, verwendete Derivate und ihre Herstellung
EP0143123A2 (de)	1985-06-05	Industrielle Verbindungen anwendbar als Zwischenprodukte in der Herstellung von in Stellung 2 substituierten 4-Hydroxy 3-Quinolincarboxamid-Derivaten und die Herstellung von diesen Zwischenprodukten
EP0173597B1 (de)	1989-12-27	Ätheroxidderivate von Zyklopropylphenolen
EP0092287B1 (de)	1987-03-25	Acetylcystein-Salze, ihre Herstellung und Verwendung
EP0099799B1 (de)	1986-03-12	Salze von alpha-Amino(und Imino)-Säure, omega-Sulfon N-substituiert, kationische Vektoren mit hoher cellularer Penetration und Herstellungsverfahren
EP0021924B1 (de)	1983-03-16	Indol-Derivate, Verfahren zu ihrer Herstellung, ihre Verwendung als Arzneimittel und sie enthaltende pharmazeutische Zusammensetzungen
EP0165155A1 (de)	1985-12-18	N-Acylaminocarbonsäurederivate und ihre Ester, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
EP0539460B1 (de)	1994-10-05	Von dialkylaminoalkyl-26-sulfonylpristinamycin iib abgeleitete salze
EP0374029B1 (de)	1992-03-25	Verwendung von substituierten Benzamiden zur Stimulierung der Gastromotorik
BE890948A (fr)	1982-02-15	Derives de l'acide anthranilique
EP0236646A1 (de)	1987-09-16	Ortho-Anisamide, Verfahren zu deren Herstellung und deren pharmazeutische Anwendungen
EP0005422B1 (de)	1982-10-27	Derivate der Omega-dialkylierten Alkankarbonsäuren, Verfahren zu ihrer Herstellung und Verwendung als Arzneimittel
LU84421A1 (fr)	1984-05-10	Sels d'acide ursodesoxycholique,leur preparation et leur utilisation
EP0176444A1 (de)	1986-04-02	Verfahren zur Herstellung von 4H-1,2,4-Triazol-Derivaten, so erhaltene neue Triazole, ihre Verwendung als Arzneimittel und sie enthaltende pharmazeutische Zusammensetzungen
CA1068270A (fr)	1979-12-18	Diamino-2,4-bromo-5 chloro-6 pyrimidines utilisables comme medicaments et procede pour leur preparation
EP0066934A1 (de)	1982-12-15	Nitrofurantoinsalze, ihre Herstellung und ihre Anwendung
FR2600065A1 (fr)	1987-12-18	Nouveaux derives de l'acide 5-((2-benzofuranyl) carbonyl) thiophene acetique, leurs sels, leurs procedes de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
BE887671A (fr)	1981-08-25	Preparations pharmaceutiques topiques contenant des sels d'acides alcane-carboxyliques ainsi que de nouveaux sels d'acides carboxyliques et leurs procedes de preparation
FR2594826A1 (fr)	1987-08-28	Nouveaux n-acyl derives d'esters amino-4 phenyle de l'acide oxo-2 pyrrolidine carboxylique 5, preparation et medicaments les contenant
WO1984001384A1 (fr)	1984-04-12	Nouveaux derives carbothio hydroximiques, leurs procedes de preparation et les compositions en renfermant
FR2538389A2 (fr)	1984-06-29	Nouveaux produits derives de l'acide 3-amino 2-oxo azetidine-1-sulfamique, nouveau procede de preparation de produits optiquement actifs, application des nouveaux produits comme medicaments et produits necessaires a leur preparation